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RESEARCH NOTE VIROLOGYBone marrow CD34+ progenitor cells may
harbour HIV-DNA even in successfully
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1) Cellular Immunology Laboratory, 2) Clinical Department and 3) Virology
Laboratory, National Institute for Infectious Diseases “Lazzaro Spallanzani”
I.R.C.C.S., Rome, ItalyAbstractThe issue about bone marrow hematopoietic progenitor cells
harbouring HIV-DNA in infected patients is still under scrutiny.
We studied nine HIV-infected individuals undergoing bone
marrow aspiration for diagnostic purposes. In all patients, even in
those receiving successful antiretroviral therapy for several years,
HIV-DNA was detected in puriﬁed CD34+ lineage-bone marrow
progenitor cells. This ﬁnding, although not conclusive due to the
low number of patients examined, adds further evidence that
current treatment strategies may be insufﬁcient to resolve latent
infection in bone marrow CD34+ hematopoietic progenitor cells.
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E-mail: veronica.bordoni@inmi.itIntroductionThe issue about HIV latent infection of CD34+ hematopoietic
progenitor cells (HPCs) in HIV-positive individuals still needsMicrobiol Infect 2015; 21: 290.e5–290.e8
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.11.003clear answers [1,2]. All studies on this topic have considered
small samples (on average, about 10 patients/paper, range
8–18) due to the difﬁculty in the enrolment of suitable patients.
Nevertheless, it has been previously demonstrated that HPCs
are infected in vivo [3–6], and more recently this has been
shown even in successfully treated patients [7]. In contrast,
others were unable to ﬁnd detectable HIV-DNA, and no HIV
replication was observed, after differentiation, in CD34+ bone
marrow (BM)-HPCs from HIV-positive patients receiving suc-
cessful antiretroviral therapy (ART) for more than 2 years [8,9].
Recently, in chronically infected subjects with undetectable
plasma HIV-RNA, we have shown that BM-HPCs are apparently
free of HIV replication, but are blunted in differentiation
capability, leaving open the question about latent HIV infection
[10]. Thus, the ability of CD34+ BM-HPC to provide a suitable
reservoir during HIV infection is still under scrutiny. In the
present study we addressed this issue by investigating whether,
in untreated or ART-treated HIV-positive patients, CD34+ BM-
HPCs may harbour HIV-DNA.
Peripheral blood (PB) and BM blood residual samples were
obtained from 9 HIV-infected patients undergoing BM aspiration
for diagnostic purposes. The present project has been approved
by the local Ethical Committee (Approval n.4 dated January 22,
2013), and signed informed consent was obtained from all
enrolled subjects. CD34+ HPCs were puriﬁed from BM mono-
nuclear cells (MNC) obtained by density gradient centrifugation,
by a two-step magnetic procedure (CD34 Diamond isolation kit,
Miltenyi Biotec Inc., San Diego, CA, USA) involving a lineage (Lin)
depletion of mature cells followed by positive CD34+ isolation
(as shown in Fig. 1a). Phenotype analysis of CD34+ HPC from
BM patients was performed by ﬂow cytometry. Samples acqui-
sition and data analysis were performed by a FACS Canto II ﬂow
cytometer (Becton Dickinson, San Jose, CA, USA) by using Diva
software. In Fig. 1b and c, an example of the enriched Lin- cells
and purity of the resulting CD34+Lin- cells is reported. The
percentage of CD34+Lin- cells was 97.6% (interquartile range
(IQR) 95.85–98.15), while the percentage of contaminating cells
deﬁned as CD34-CD4+ was 0.1% (IQR 0–0.15) (Fig. 1c, Fig. 2a).
Proviral HIV-DNA load was measured by long terminal repeat
(LTR)-speciﬁc quantitative real-time PCR, and normalized to cell
number by human telomerase reverse transcriptase (hTERT)
gene [11,12]. Statistical comparison (Mann-Whitney U test) and
correlations (Spearman rank test) were assessed using GraphPad
Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
Clinical and experimental data from enrolled patients are
shown in Fig. 2a. HIV+ patients underwent BM aspiration because
of clinical indication as follows: suspicion of opportunistic infec-
tion (all patients), pancytopenia (n = 5), fever of unknown origin
(n = 2), and suspicion of lymphoma (n = 1). Typical HIV-relatedious Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Flow cytometry analysis of puriﬁcation method used to analyse HIV-DNA in CD34+ hematopoietic progenitor cells (HPC). (a) Method used to
isolate CD34+ HPC. CD34+ cells were ﬁrst enriched from bone marrow mononuclear cells (BM-MNC) using indirect magnetic labelling of Lineage
(Lin) positive cells. Highly pure CD34+Lin- populations were then obtained by a positive selection of CD34+ HPC using a direct magnetic labelling of
lineage negative populations. (b) One representative ﬂow cytometry analysis showing the percentage of CD34+ and CD4+ cells on Lineage-depleted
populations of BM-MNC and (c) the corresponding purity of the CD34+Lin- cells obtained.
CMI Bordoni et al. Bone marrow CD34+ progenitor cells 290.e6bone marrow morphology (from normocellular (n = 5) to
hypocellular (n = 4) marrow) was observed with dysplastic
changes most commonly seen in the granulocytic series. Plasma
cells were often increased. Two opportunistic infections (leish-
maniasis) were found in the bone marrow. Five patients were
ART-untreated (HIV-RNA, median 5.92 × 105 cp/mL, IQR
2.6 × 104–2.6 × 106), while four patients were on successful ART
(HIV-RNA <50 cp/mL). Patients treated with ART received
antiretrovirals for a median of 78 months (IQR 10–168months).
Haematological features were not signiﬁcantly different be-
tween the ART-treated and untreated patients. As expected,
the proportion of peripheral blood CD4+ cells was higher in
ART-treated patients (24.6%; IQR 20.45–33.20) in comparison
to untreated patients (median 11.9%; IQR 9.15–22.3; p = 0.05)
(Fig. 2a). Since enrolled patients presented clinical indication for
BM aspiration, they showed hematologic abnormalities,
including deep lymphopenia. Thus, the absolute peripheral
blood CD4+ T cell counts did not signiﬁcantly differ amongClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InART-treated and untreated patients (median 127.5/mm3, IQR
73–1121 vs. 245/mm3, IQR 125–361, p = 0.36). Total BM-
MNCs in untreated and ART-treated patients were not signif-
icantly different (median 5 × 107, IQR 1.6 × 107–1 × 108/10 mL,
vs. median 8 × 107, IQR 2 × 107–2.5 × 108/10 mL, respectively,
p = 0.36). On the contrary, the yield of CD34+Lin- cells was
higher from treated patients with respect to untreated patients
(median 1.1 × 105, IQR 9.0 × 104–3.96 × 105, vs. median
7.5 × 104, IQR 3.0 × 104–2.84 × 104, p = 0.05).
The analysis of HIV proviral DNA, reported in Fig. 2a, in-
dicates that the levels found in total BM were not signiﬁcantly
different from those in PB (Fig. 2b, left and middle panels,
p = 0.34). Interestingly, while virtually all patients harboured
HIV-DNA in CD34+ BM-HPCs, irrespective of being treated or
not, the amount of HIV-DNA was signiﬁcantly lower in patients
on effective ART as compared to untreated patients (median
7 cp/104 cells, IQR 3.5.5–8.5 vs. 72 cp/104 cells, IQR 34.5–433,
p = 0.05, Fig. 2b, right panel). Finally, a signiﬁcant positivefectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 290.e5–290.e8
FIG. 2. Analysis of HIV-DNA in untreated and antiretroviral therapy (ART)-treated HIV patients. (a) Clinical and experimental data from enrolled
subjects. (b) HIV-DNA levels in bone marrow, peripheral blood, and CD34+Lin- cells from untreated and ART-treated patients (left, middle, and right
panel). Bars show medians with range. (c) Linear regression analysis between HIV-DNA levels in CD34+Lin- BM-HPCs and plasma HIV-RNA levels;
r = 0.6528, p = 0.0333. HIV-DNA levels were measured by PCR and then normalized to cell equivalents by using hTERT as reference.
290.e7 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIcorrelation between plasma HIV-RNA and CD34+ BM-HPCs
HIV-DNA was observed (r = 0.6528, p = 0.03, Fig. 2c); in
contrast, no correlation was found with PB-MNC HIV-DNA.
Interestingly, HIV+ naive subjects display signiﬁcantly higher
HIV-DNA in CD34+ BM-HPS, but not in PB-MNC and BM-
MNC. Many different mechanisms may cause this discrepancy,
included wide dispersions due to the small sample size. This
issue will be investigated in the ongoing work.
The ambitious aim of HIV eradication or functional cure
critically depends on the full understanding of viral reservoirs
establishment mechanisms [13]. We observe that HIV-DNA
may be detected in CD34+Lin- BM-HPCs regardless of ART,
and even after many years of treatment. The difference be-
tween our ﬁndings and those from other groups, who were
unable to detect HIV-DNA in isolated CD34+ BM-HPCs
[8,9,14,15], may be due to differences in study populations. In
particular, our patients selectively included patients with HIV-
associated myelodysplasia or with clinical indication for BM
aspiration, and this may represent a major confounder. Indeed,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectit is possible that HPC in these patients are impaired and more
susceptible to HIV infection than HPC of HIV-infected in-
dividuals without major hematologic abnormalities.
Moreover, technical issues, such as the method used for
CD34+ HPCs isolation leading to a non-homogenous cell
population with the enrichment of a speciﬁc subset [16], may
inﬂuence the results. Durand et al. have hypothesized that
contamination by HIV-infected CD4 T cells could produce false-
positive results in beads-enriched HPCs [8], such as those in the
Carter et al. work [7]. In our study we used a double-bead
method to isolate very pure CD34+ cells (purity always >97.6
%). It is interesting to note that the sorter method used in the
Durand et al. study did not consider as “contaminating” the
population of CD3–CD4+ cells present in the bone marrow
and in the enriched fraction [8]. Moreover, the sorter method
used by Josefsson to isolate CD34+Lin- cells gave a purity of
76.7% [9]. In our view, our data may exclude the possibility that
a contamination of <0.1% CD34-CD4+ cells may totally ac-
count for the proviral load found in the CD34+Lin- population.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 290.e5–290.e8
CMI Bordoni et al. Bone marrow CD34+ progenitor cells 290.e8Our work has limitations and cannot be considered conclu-
sive due to the low number of patients recruited; however,
work is in progress aimed at both increasing sample size and
widening the representation of HIV-associated clinical scenarios.
In conclusion, our results suggest that CD34+Lin- BM-HPCs
may harbour HIV genomes, and that HIV-DNA levels in
CD34+Lin- BM-HPCs may correlate with the extent of plasma
viremia. Bone marrow infection seems to be persistent even in
the context of plasma HIV-RNA suppression after several years
of ART. Further critical issues need to be evaluated, such as
whether the infection of progenitor BM cells is productive, and/
or how this may impact the proliferation and differentiation
functional capabilities of BM-HPCs.Transparency declarationThe authors have no conﬂicts of interest to declare.AcknowledgementsThe authors gratefully acknowledge the patients who made this
study possible.
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